for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pfizer Inc.

PFE.N

Latest Trade

42.81USD

Change

0.02(+0.05%)

Volume

6,537,171

Today's Range

42.70

 - 

43.19

52 Week Range

33.36

 - 

43.73

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
42.79
Open
42.88
Volume
6,537,171
3M AVG Volume
542.16
Today's High
43.19
Today's Low
42.70
52 Week High
43.73
52 Week Low
33.36
Shares Out (MIL)
5,597.69
Market Cap (MIL)
239,637.30
Forward P/E
10.71
Dividend (Yield %)
3.64

Next Event

Q3 2021 Pfizer Inc Earnings Release

Latest Developments

更多

U.S. CDC Says Delivered 400,675,525 Doses Of COVID-19 Vaccine As Of July 31

U.S. CDC Says Delivered 399,090,105 Doses Of Covid-19 Vaccine As Of July 30

FDA, Under Pressure, Plans To Accelerate Review Of Pfizer’s Covid-19 Vaccine For Full Approval - Stat News

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pfizer Inc.

Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks.

Industry

Biotechnology & Drugs

Contact Info

235 E 42ND ST

NEW YORK, NY

10017-5703

United States

+1.212.5732323

https://www.pfizer.com/

Executive Leadership

Albert Bourla

Chairman of the Board, Chief Executive Officer

John D. Young

Chief Business Officer, Group President

Frank A. D'amelio

Chief Financial Officer, Executive Vice President - Global Supply

Angela Hwang

Group President, Pfizer Biopharmaceuticals Group

Lidia Fonseca

Executive Vice President, Chief Technology Officer and Digital Officer

Key Stats

2.58 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

53.6K

2019

51.8K

2020

41.9K

2021(E)

78.1K
EPS (USD)

2018

3.000

2019

2.950

2020

2.220

2021(E)

3.997
Price To Earnings (TTM)
19.56
Price To Sales (TTM)
4.32
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
14.16
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

UPDATE 2-Pfizer and Moderna raise prices for COVID-19 vaccines in EU- FT

Pfizer Inc and Moderna Inc have raised the prices of their COVID-19 vaccines in their latest European Union supply contracts, the Financial Times reported https://on.ft.com/3j8mbTb on Sunday.

Pfizer and Moderna raises prices for its COVID-19 vaccines in EU- FT

Pfizer Inc and Moderna Inc has raised the prices of its COVID-19 vaccine in the latest European Union supply contracts, The Financial Times reported https://on.ft.com/3j8mbTb on Sunday.

UPDATE 6-Pfizer says 2021 COVID-19 vaccine sales to top $33.5 bln, sees need for boosters

Pfizer Inc on Wednesday raised its 2021 sales forecast for its COVID-19 vaccine by 29% to $33.5 billion, and said it believes people will need a third dose of the shot developed with German partner BioNTech to keep protection against the virus high.

Pfizer raises estimates for 2021 sales of COVID-19 vaccine to $33.5 bln

Pfizer Inc on Wednesday raised its forecast for sales of the COVID-19 vaccine that it developed with Germany's BioNTech to $33.5 billion from $26 billion, the second increase this year in the face of a global scramble for the shots. (Reporting by Manas Mishra in Bengaluru...

Italian regulator endorses Moderna COVID-19 vaccine for teens

Italian regulators approved the use of Moderna's COVID-19 vaccine for children 12-17 years old, making it the second shot endorsed for adolescents, alongside that of Pfizer.

UPDATE 1-Moderna in talks with FDA to expand COVID-19 vaccine pediatric study

Moderna Inc is in talks with U.S. regulators to expand the size of an ongoing trial testing its COVID-19 vaccines in children aged between five and 11, the drugmaker said on Monday.

FDA asks Pfizer and Moderna to expand COVID-19 vaccine pediatric studies- NYT

U.S. regulators have asked Pfizer Inc -BioNTech and Moderna Inc to expand the size of ongoing trials testing their COVID-19 vaccines in children aged between five and 11, the New York Times reported on Monday.

Mixed AstraZeneca-Pfizer shot boosts COVID antibody level - study

A mixed vaccination of first AstraZeneca and then a Pfizer COVID-19 shot boosted neutralizing antibody levels by six times compared with two AstraZeneca doses, a study from South Korea showed.

UPDATE 4-United States buys 200 mln more doses of Pfizer/BioNTech COVID-19 vaccine

Pfizer Inc and German partner BioNTech said on Friday the U.S. government has purchased 200 million additional doses of their COVID-19 vaccine to help with pediatric vaccination as well as possible booster shots - if they are needed.

Australia's drug regulator approves Pfizer COVID-19 vaccine for 12 to 15-year-olds

Australia's drug regulator has approved Pfizer's COVID-19 vaccine for use with 12 to 15-year-olds, Federal Health Minister Greg Hunt said on Friday, as the country fights an outbreak of the Delta variant in three states.

UPDATE 1-South African firm to help make Pfizer/BioNTech COVID vaccine

Pfizer and BioNTech have struck a deal for South Africa's Biovac Institute to help manufacture around 100 million doses a year of their COVID-19 vaccine for the African Union, the firms said on Wednesday.

Norway, Lithuania swap J&J, Pfizer vaccines to speed up inoculation

Norway on Wednesday signed a deal to swap 100,000 doses of its unused shots made by Johnson & Johnson with Lithuania in return for an equal number of doses from Pfizer in a move to speed up inoculations.

UPDATE 1-U.S. to allow temporary rise in impurities in anti-smoking drug

The U.S. drug regulator said on Friday it will temporarily allow manufacturers to distribute the anti-smoking drug varenicline with elevated levels of an impurity that may cause cancer, to maintain availability after Pfizer Inc halted distribution of its Chantix branded...

U.S. FDA to temporarily allow distribution of anti-smoking pill with some impurities

The U.S. drug regulator said on Friday it will temporarily allow manufacturers to distribute versions of Pfizer Inc's anti-smoking drug Chantix with elevated levels of an impurity that may cause cancer, in order to maintain supplies.

COVID SCIENCE-Smell tests can screen for COVID; Cancer patients need both Pfizer doses

Here is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

UPDATE 2-U.S. FDA sets January target to decide on approval of Pfizer's COVID-19 shot

The U.S. health regulator will review Pfizer and German partner BioNTech SE's application for full approval of their COVID-19 vaccine in people 16 years and older by January, the companies said on Friday.

UPDATE 2-Pfizer agrees to pay $345 mln to resolve EpiPen pricing lawsuit

Pfizer Inc has agreed to pay $345 million to resolve claims by consumers who say they overpaid for EpiPens due to anticompetitive practices by the drugmaker and the company that markets the emergency allergy treatment, Mylan.

Pfizer agrees to pay $345 mln to resolve EpiPen pricing lawsuit

Pfizer Inc has agreed to pay $345 million to resolve claims by consumers who claim they overpaid for EpiPens due to anticompetitive and unfair practices by the drugmaker and the company that markets the emergency allergy treatment, Mylan.

UPDATE 3-Pfizer, BioNTech deny talks with Thai Thonburi Healthcare on vaccines

Pfizer and Germany's BioNTech denied on Thursday that they were in talks with Thailand's Thonburi Healthcare Group Pcl for a deal to import 20 million doses of the coronavirus vaccine to the Southeast Asian country.

UPDATE 1-Panama allows Pfizer-BioNTech vaccine for those as young as 12

Panama's Health Ministry said on Monday it would allow emergency use of the Pfizer Inc-BioNTech vaccine against COVID-19 for children aged 12 years and older but gave no details on when it would start.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up